Leading HIV Researchers Reflect on Breakthroughs, Challenges at CROI 2026

Why It Matters

Funding gaps threaten the scalability of new HIV therapies, making sustained investment critical for worldwide treatment equity.

Key Takeaways

• Funding gaps threaten HIV treatment access
• GLP‑1 agonists explored as anti‑inflammatory adjuncts
• Hepatitis B screening vital for long‑acting ART switches
• Global guidelines must reflect diverse Southern populations
• Immunotherapy combos may enhance viral suppression

Pulse Analysis

The 2026 Conference on Retroviruses and Opportunistic Infections (CROI) showcased a watershed moment for HIV research, gathering leading virologists, clinicians, and policy advocates. While presenters highlighted unprecedented advances in antiretroviral regimens and prevention tools, a recurring theme was the fragility of the funding ecosystem that underpins these breakthroughs. Speakers such as Jeanne Marrazzo warned that dwindling U.S. appropriations could jeopardize access to life‑saving therapies, especially for marginalized groups. The conference therefore served both as a celebration of scientific progress and a rallying call for sustained investment.

Scientific innovation took center stage, with several investigators proposing novel adjuncts to standard therapy. Steven Grinspoon emphasized the anti‑inflammatory potential of GLP‑1 receptor agonists, suggesting they could complement statins to curb chronic immune activation in people living with HIV. Meanwhile, Victor Appay outlined early data on combining potent antiretrovirals with immune‑modulating agents to achieve deeper viral control. Clinicians also stressed practical considerations: Gerald Pierone reminded providers to screen for hepatitis B before transitioning patients to long‑acting injectable regimens, a step that could prevent reactivation and improve outcomes.

Beyond the laboratory, the dialogue turned to equity and global relevance. Juan Medina argued that one‑size‑fits‑all guidelines ignore the epidemiological and socioeconomic realities of the global South, urging the development of region‑specific protocols. Advocacy voices, exemplified by Peter Staley, highlighted recent legal victories that protect PrEP access against authoritarian push‑back. The consensus was clear: integrating cutting‑edge science with culturally attuned policies and robust funding will determine whether the momentum generated at CROI translates into tangible reductions in HIV incidence worldwide.